Faron Pharmaceuticals Oy (DI) (FARN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

235.00p
   
  • Change Today:
    -5.00p
  • 52 Week High: 250.00p
  • 52 Week Low: 92.50p
  • Currency: UK Pounds
  • Shares Issued: 111.60m
  • Volume: 23,310
  • Market Cap: £262.26m

Latest ShareCast News

Faron Pharmaceuticals appoints chief business officer

By Josh White

Date: Wednesday 21 May 2025

(Sharecast News) - Faron Pharmaceuticals announced the appointment of Ralph Hughes as its chief business officer on Wednesday, effective 28 May, as the clinical-stage biopharma firm sharpened its focus on commercial strategy, business development and market access.

Faron enters financing arrangement with Heights Capital Management entity

By Josh White

Date: Thursday 03 Apr 2025

(Sharecast News) - Faron Pharmaceuticals announced on Thursday that it has entered into a financing arrangement with an entity managed by Heights Capital Management for up to €35m in convertible bonds, issuing an initial €15m tranche to repay existing debt and bolster its financial position ahead of a key clinical readout.

Faron identifies final patient in BEXMAB phase two study

By Josh White

Date: Friday 31 Jan 2025

(Sharecast News) - Faron Pharmaceuticals announced on Friday that it has identified the final patient for its BEXMAB phase two dose optimisation study in refractory or relapsed myelodysplastic syndrome (r/r MDS) and its phase one and two study in frontline high-risk (HR) MDS.

Faron Pharmaceuticals reports regulatory progres... 02-Dec-2024 ShareCast
Faron announces promising MDS trial results 27-Nov-2024 ShareCast
Faron Pharmaceuticals files new patent for Cleve... 11-Nov-2024 ShareCast
Faron Pharmaceuticals candidate gets FDA fast tr... 27-Aug-2024 ShareCast
Faron gets positive FDA feedback on bexmarilimab... 11-Jul-2024 ShareCast
Faron Pharmaceuticals extends funding agreement ... 30-Apr-2024 ShareCast
Faron Pharmaceuticals CFO stands down 15-Apr-2024 ShareCast
Faron Pharmaceuticals taps Juho Jalkanen for CEO 08-Apr-2024 ShareCast
Faron shares jump on encouraging trial data 18-Mar-2024 ShareCast
Faron Pharmaceuticals reports year of clinical p... 13-Mar-2024 ShareCast
Faron Pharmaceuticals shores up cash with EUR 3.... 04-Mar-2024 ShareCast
Faron launches second phase of leukaemia treatme... 09-Jan-2024 ShareCast
Faron unveils promising antibody study results 11-Dec-2023 ShareCast
Faron publishes cancer immunotherapy study findi... 07-Dec-2023 ShareCast
Faron reveals details of next stage of bexmarili... 06-Nov-2023 ShareCast
Faron Pharmaceuticals upbeat on latest data in b... 11-Oct-2023 ShareCast
Faron Pharmaceuticals names interim chief medica... 21-Sep-2023 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

FARN Market Data

Currency UK Pounds
Share Price 235.00p
Change Today -5.00p
% Change -2.08 %
52 Week High 250.00p
52 Week Low 92.50p
Volume 23,310
Shares Issued 111.60m
Market Cap £262.26m

FARN Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
Market averageMarket averageMarket averageMarket averageMarket average
40.43% below the sector average40.43% below the sector average40.43% below the sector average40.43% below the sector average40.43% below the sector average
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
78.72% above the sector average78.72% above the sector average78.72% above the sector average78.72% above the sector average78.72% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 2
Neutral 0
Sell 0
Strong Sell 1
Total 4
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

FARN Dividends

No dividends found

Trades for 23-May-2025

Time Volume / Share Price
14:34 80 @ 235.00p
14:23 500 @ 230.00p
13:58 2,139 @ 236.50p
12:29 1,000 @ 250.00p
11:20 399 @ 249.00p

FARN Key Personnel

CFO Yrjö E K Wichmann
CEO Juho Jalkanen
Chair Tuomo Pätsi

Top of Page